State Key Laboratory of Organ Failure Research, Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China.
JMIR Public Health Surveill. 2024 Feb 28;10:e53982. doi: 10.2196/53982.
The high prevalence of hepatitis A delivered a blow to public health decades ago. The World Health Organization (WHO) set a goal to eliminate viral hepatitis including hepatitis A by 2030. In 2008, hepatitis A vaccines were integrated into the Expanded Program on Immunization (EPI) in China to alleviate the burden of hepatitis A, although the effectiveness of the EPI has not been well investigated.
We aimed to evaluate the intervention effect at both provincial and national levels on the incidence of hepatitis A in the Chinese mainland from 2005 to 2019.
Based on the monthly reported number of hepatitis A cases from 2005 to 2019 in each provincial-level administrative division, we adopted generalized additive models with an interrupted time-series design to estimate province-specific effects of the EPI on the incidence of hepatitis A among the target population (children aged 2-9 years) from 2005 to 2019. We then pooled province-specific effect estimates using random-effects meta-analyses. We also assessed the effect among the nontarget population and the whole population.
A total of 98,275 hepatitis A cases among children aged 2-9 years were reported in the Chinese mainland from 2005 to 2019, with an average annual incidence of 5.33 cases per 100,000 persons. Nationally, the EPI decreased the hepatitis A incidence by 80.77% (excess risk [ER] -80.77%, 95% CI -85.86% to -72.92%) during the study period, guarding an annual average of 28.52 (95% empirical CI [eCI] 27.37-29.00) cases per 100,000 persons among the target children against hepatitis A. Western China saw a more significant effect of the EPI on the decrease in the incidence of hepatitis A among the target children. A greater number of target children were protected from onset in Northwest and Southwest China, with an excess incidence rate of -129.72 (95% eCI -135.67 to -117.86) and -66.61 (95% eCI -67.63 to -64.22) cases per 100,000 persons on average, respectively. Intervention effects among nontarget (ER -32.88%, 95% CI -39.76% to -25.21%) and whole populations (ER -31.97%, 95% CI -39.61% to -23.37%) were relatively small.
The EPI has presented a lasting positive effect on the containment of hepatitis A in the target population in China. The EPI's effect on the target children also provided a degree of indirect protection for unvaccinated individuals. The continuous surveillance of hepatitis A and the maintenance of mass vaccination should shore up the accomplishment in the decline of hepatitis A incidence to ultimately achieve the goal set by the WHO.
甲型肝炎的高发病率在几十年前对公共卫生造成了冲击。世界卫生组织(WHO)设定了到 2030 年消除包括甲型肝炎在内的病毒性肝炎的目标。2008 年,甲型肝炎疫苗被纳入中国扩大免疫规划(EPI),以减轻甲型肝炎的负担,尽管 EPI 的效果尚未得到很好的调查。
我们旨在评估 2005 年至 2019 年期间,EPI 对中国内地甲型肝炎发病率的省级和国家级干预效果。
基于 2005 年至 2019 年各省级行政区每月报告的甲型肝炎病例数,我们采用广义加性模型和中断时间序列设计,估计 2005 年至 2019 年 EPI 对目标人群(2-9 岁儿童)中甲型肝炎发病率的省级特异性影响。然后,我们使用随机效应荟萃分析汇总省级特异性效果估计值。我们还评估了非目标人群和全人群的效果。
2005 年至 2019 年期间,中国大陆共报告 98275 例 2-9 岁儿童甲型肝炎病例,年均发病率为每 10 万人 5.33 例。全国范围内,EPI 在研究期间将甲型肝炎发病率降低了 80.77%(超额风险[ER]-80.77%,95%置信区间[CI]-85.86%至-72.92%),每年为目标儿童平均预防 28.52 例(95%经验[e]CI[置信区间]27.37-29.00)每 100,000 人患甲型肝炎。中国西部地区的 EPI 对目标儿童甲型肝炎发病率下降的影响更为显著。西北地区和西南地区有更多的目标儿童受到保护,免于发病,平均发病率分别为 129.72(95%eCI-135.67 至-117.86)和 66.61(95%eCI-67.63 至-64.22)每 100,000 人。非目标人群(ER-32.88%,95%CI-39.76%至-25.21%)和全人群(ER-31.97%,95%CI-39.61%至-23.37%)的干预效果相对较小。
EPI 对中国目标人群甲型肝炎的控制产生了持久的积极影响。EPI 对目标儿童的影响也为未接种疫苗的个体提供了一定程度的间接保护。对甲型肝炎的持续监测和大规模疫苗接种的维持应巩固在降低甲型肝炎发病率方面取得的成果,以最终实现世卫组织设定的目标。